- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
RSV Vaccines for Adults: Gaps in Understanding
Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.
The FDA has approved two vaccines against respiratory syncytial virus (RSV) for adults, sold under the brand names Arexvy and Abrysvo, and the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends the RSV vaccination for those 60 or older under shared clinical decision-making.
Angela Branche, M.D., discussed the gaps in the understanding of RSV vaccination at the ID Week 2023 meeting in Boston earlier this year.
"If you are in your mid-to late 70s, if you're in your 80s, if you live in a long-term care facility or assisted living facility, I have very, very little reservation and strongly recommend RSV vaccines for those folks," said Branche. "But if you are in your 60s, it's worth having a conversation with your provider about it."
Promising Results for Investigational mRNA Vaccine Against CMV
February 16th 2024A study found that the mRNA-1647 vaccine candidate developed by Moderna elicited strong immune responses. The mRNA vaccine is now in phase 3 clinical trials to determine its effectiveness in protecting against CMV.
Read More
